LUZHU BIOTECH-B (02480): Recombinant RSV vaccine receives clinical trial approval in China

LUZHU BIOTECH-B (02480) announced that the Group's developed recombinant respiratory syncytial virus (RSV) vaccine (recombinant RSV vaccine) has been approved by the National Medical Products Administration of the People's Republic of China (China) to conduct clinical trials in China. This product is a recombinant protein vaccine candidate independently developed by the Group for the prevention of lower respiratory tract disease (LRTD) caused by RSV. It is a liquid formulation vaccine containing an aluminum adjuvant, using RSV pre-fusion F (Pre-F) protein antigen. The approval of this clinical trial has laid a solid foundation for the Group's subsequent development of recombinant protein vaccine candidates.